Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses

Experimental Hematology

Volumn 34, Issue 10, 2006, Pages 1403-1412

  Weigel, Brenda J ^a   Panoskaltsis Mortari, Angela ^a   Diers, Miechaleen ^a   Garcia, Melissa ^a   Lees, Chris ^a   Krieg, Arthur M ^b   Chen, Wei ^a   Blazar, Bruce R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG 7909; CPG OLIGODEOXYNUCLEOTIDE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LYSATE; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL; TUMOR CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; CELL-FREE SYSTEM; DENDRITIC CELLS; FEMALE; INTERFERON TYPE II; LEUKEMIA, MYELOCYTIC, ACUTE; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; OLIGODEOXYRIBONUCLEOTIDES; SPLEEN; T-LYMPHOCYTES; VACCINATION;

MURINAE;

EID: 33748560173     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2006.05.011     Document Type: Article

References (52)

1. Fields R.C., Shimizu K., and Mule J.J. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 95 (1998) 9482-9487
2. Zitvogel L.Z., Mayordomo J.I., Tjandrawan T., et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183 (1996) 87-97
3. Ashley D.M., Faiola B., Nair S., Hale L.P., Bigner D.D., and Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induced antitumor immunity against central nervous system tumors. J Exp Med 186 (1997) 1177-1182
4. Nestle F.O., Alijagic S., Gilliet M., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4 (1998) 328-332
5. Hsu F.J., Benike C., Fagnoni F., et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2 (1996) 52-58
6. Reichardt V.L., Okada C.Y., Liso A., et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study. Blood 93 (1999) 2411-2419
7. Dhodapkar M.V., Steinman R.M., Sapp M., et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 104 (1999) 173-180
8. Sauter B., Albert M.L., Francisco L., Larsson M., Somersan S., and Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191 (2000) 423-433
9. Kreig A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20 (2002) 709-760
10. Klinman D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 4 (2004) 249-258
11. Wagner H. The immunobiology of the TLR9 subfamily. Trends Immunol 25 (2004) 381-386
12. Weiner G.J., Lui H.M., Wooldridge J.E., Dahle C.E., and Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effects as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A 94 (1997) 10833-10837
13. Hartmann G., and Krieg A.M. Mechanism and function of a newly identified CpG DNA motif in human primary B-cells. J Immunol 164 (2000) 944-953
14. Wooldridge J.E., Ballas Z., Krieg A.M., and Weiner G.J. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 89 (1997) 2994-2998
15. Krieg A.M., Love-Homan L., Yi A.K., and Harty J.T. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol 161 (1998) 2428-2434
16. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., and Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186 (1997) 1623-1631
17. Klinman D.M., Yi A.K., Baucage S.L., Conover J., and Krieg A.M. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A 93 (1996) 2879-2883
18. Blazar B.R., Krieg A.M., and Taylor P.A. Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naïve and bone marrow transplant recipients. Blood 98 (2001) 1217-1225
19. Friedberg J.W., Kim H., McCauley M., et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 105 (2005) 489-495
20. th World Conference on Lung Cancer, 2005.
21. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115 (2005) 739-746
22. Cooper C.L., Davis H.L., Morris M.L., et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24 (2004) 693-701
23. Cooper C.L., Davis H.L., Angel J.B., et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 19 (2005) 1473-1479
24. Siegrist C.A., Pihlgren M., Tougne C., et al. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 23 (2004) 615-622
25. Pawlowska A.B., Hashino S., McKenna H., et al. In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells proved protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice. Blood 97 (2001) 1474-1482
26. Weigel B.J., Nath N., Taylor P.A., et al. Comparative analysis of murine marrow derived dendritic cells generated by FLT3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of anti-leukemia responses. Blood 100 (2002) 4169-4176
27. Kjaergaard J., Shimizu K., and Shu S. Electrofusion of syngenic dendritic cells and tumor generates potent therapeutic vaccine. Cell Immunol 225 (2003) 65-74
28. Shimizu K., Kuriyama H., Kjaergaard J., Lee W., Tanaka H., and Shu S. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother 27 (2004) 265-272
29. Wang J., Saffold S., Cao X., Krauss J., and Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 161 (1998) 5516-5524
30. Gong J., Koido S., Kato Y., et al. Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk Res 28 (2004) 1303-1312
31. Galea-Lauri J., Darling D., Mufti G., Harrison P., and Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother 51 (2002) 229-310
32. Sauer M.G., Ericson M.E., Weigel B.J., et al. A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytoxic T cells (CTLs). Cancer Res 64 (2004) 3914-3921
33. Inaba K., Inaba M., Romani N., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factors. J Exp Med 176 (1992) 1693-1702
34. George TC, Fanning SL, Fitzgeral-Bocarsly P, et al. Distinguishing modes of cell death using the ImageStream Multispectral Imaging Flow Cytometer. Cytometry. 59A:237-245.
35. Simmons H.M., Oseth L., Nguyen P., O'Leary M., Conklin K.F., Hirsch B., et al. Cytogenetic and molecular heterogeneity of 7q36/12p13 rearrangements in childhood AML. Leukemia 16 (2002) 2408-2416
36. + T-cell immune response to murine myeloid leukemia. Blood 85 (1995) 2498-2506
37. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods 145 (1991) 185-192
38. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies: I. Data analysis. J Immunol 126 (1981) 1614-1619
39. Coligan J.E., Kruisbeek A.M., Margulies D.H., Shevach E.M., and Strober W. ELISPOT assay to detect cytokine-secreting murine and human cells. Current Protocols in Immunology 6 (1999) 19
40. Siders W.M., Vergilis K.L., Johnson C., Shields J., and Kaplan J.M. Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol Ther 7 (2003) 498-505
41. Klammer M., Waterfall M., Samuel K., Turner M.L., and Roddie P.H. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia. Br J Haematol 129 (2005) 340-349
42. Trevor K.T., Cover C., Ruiz Y.W., et al. Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application. Cancer Immunol Immunother 53 8 (2004 Aug) 705-714
43. Koido S., Ohana M., Liu C., et al. Dendritic cells fused with human cancer cells: Morphology, antigen expression, and T cell stimulation. Clin Immunol 113 (2004) 261-269
44. Gottfried E., Krieg R., Eichelberg C., Andreesen R., Mackensen A., and Krause S.W. Characterization of cells prepared by dendritic cell-tumor cell fusion. Cancer Immun 2 (2002) 1-11
45. Scott-Taylor T.H., Pettengell R., Clarke I., et al. Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim Biophys Acta 1500 (2000) 265-279
46. Lindner M., and Schirrmacher V. Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylene-gycol versus electro-fusion protocols. Eur J Clin Invest 32 (2002) 207-217
47. Morse M.A., Coleman R.E., Akabani G., Niehaus N., Coleman D., and Lyerly H.K. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59 1 (1999 Jan 1) 56-58
48. Hayashi T., Tanaka H., Tanaka J., et al. Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol 104 (2002) 14-20
49. Cranmer L.D., Trevor K.T., and Hersh E.M. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 53 4 (2004 Apr) 275-306
50. Labeur M.S., Roters B., Pers B., et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 162 (1999) 168-175
51. Furumoto K., Soares L., Engleman E.G., and Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest 113 5 (2004 Mar) 774-783
52. Hiraoka K., Yamamoto S., Otsuru S., et al. Enhanced tumor-specific long-term immunity of hemagglutinating virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. J Immunol 173 (2004) 4292-4307